Breaking News Instant updates and real-time market news.

A

Agilent

$61.19

-1.6 (-2.55%)

, ABT

Abbott

$60.76

-1.17 (-1.89%)

04:55
06/26/18
06/26
04:55
06/26/18
04:55

American Diabetes Association to hold a conference

78th Scientific Sessions of the ADA will be held in Orlando, FL on June 22-26.

A

Agilent

$61.19

-1.6 (-2.55%)

ABT

Abbott

$60.76

-1.17 (-1.89%)

AKCA

Akcea Therapeutics

$26.37

0.13 (0.50%)

AMGN

Amgen

$185.32

0.46 (0.25%)

AZN

AstraZeneca

$34.97

-0.085 (-0.24%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$65.11

0.48 (0.74%)

DXCM

DexCom

$95.48

-4.04 (-4.06%)

LLY

Eli Lilly

$85.82

-0.08 (-0.09%)

IRWD

Ironwood

$18.66

-0.69 (-3.57%)

JNJ

Johnson & Johnson

$122.70

-0.11 (-0.09%)

MDT

Medtronic

$86.73

-0.07 (-0.08%)

MNKD

MannKind

$2.02

0.04 (2.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.61

0.22 (15.83%)

TNDM

TNDM

SNY

Sanofi

$40.48

0.5 (1.25%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.30

-0.46 (-9.66%)

REGN

Regeneron

$327.60

-4.22 (-1.27%)

PODD

Insulet

$91.35

-6.02 (-6.18%)

NVO

Novo Nordisk

$46.98

0.14 (0.30%)

MRK

Merck

$61.07

-0.39 (-0.63%)

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 26

    Jun

A Agilent
$61.19

-1.6 (-2.55%)

05/15/18
COWN
05/15/18
UPGRADE
COWN
Outperform
Agilent upgraded to Outperform from Market Perform at Cowen
05/15/18
BARD
05/15/18
NO CHANGE
Target $77
BARD
Outperform
Agilent core growth slowing, but underlying business healthy, says Baird
Baird analyst Catherine Ramsey Schulte said Agilent's Q2 growth hit the guidance midpoint, but fell short of expectations due to unforeseen headwinds in China and ICP/MS shipment timing. She noted management remains bullish on end-market outlooks and she still believes they are being conservative with guidance. Although the company's core growth is slowing, she said the underlying business is healthy. Schulte reiterated her Outperform rating and lowered her price target to $77 from $78 on Agilent shares.
05/15/18
JEFF
05/15/18
NO CHANGE
Target $80
JEFF
Buy
Agilent pullback a buying opportunity, says Jefferies
Jefferies analyst Brandon Couillard recommends using the post-earnings pullback in shares of Agilent Technologies as a buying opportunity. Guidance was maintained, despite dilution from Lasergen, and does not yet capture accretion from the pending AATI deal, Couillard tells investors in a research note. He sees no reason to alter his positive thesis and keeps a Buy rating on Agilent with a slightly reduced price target of $80.
06/08/18
BARD
06/08/18
NO CHANGE
Target $77
BARD
Outperform
Agilent recent weakness a buying opportunity, says Baird
Baird analyst Catherine Ramsey Schulte attended Agilent's analyst day and said her positive outlook on the company remains unchanged. She continues to expect strong core growth and margin expansion to help drive above market performance over the next several years. Schulte said she would use recent weakness as a buying opportunity and reiterated her Outperform rating and $77 price target on Agilent shares.
ABT Abbott
$60.76

-1.17 (-1.89%)

05/03/18
LSCM
05/03/18
NO CHANGE
Target $76
LSCM
Buy
Surmodics price target raised to $76 from $38 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for Surmodics (SRDX) to $76 after reconsidering the way he values the shares. The existing business is worth what the stock is trading for today, and SurVeil, the two other "high potential" products considered in the Abbott (ABT) agreement and the roughly 15 510 (K) products Surmodics is developing are worth about the same, O'Neil tells investors in a research note following the company's Q2 results. He keeps a Buy rating on the shares.
06/11/18
PIPR
06/11/18
NO CHANGE
Target $32.5
PIPR
Overweight
Piper doesn't see regulatory issues for possible Stryker, Boston Scientific deal
Piper Jaffray analyst Matt O'Brien believes regulatory constraints from Stryker's (SYK) potential acquisition of Boston Scientific (BSX) "should not be much of an issue" given the little overlap between the businesses. The deal structure would be the biggest issue facing Stryker as the company would likely have to lever up heavily to acquire Boston Scientific, O'Brien tells investors in a research note. The analyst believes a transaction could occur in the $52B-$54B range, assuming a typical medtech takeout premium of 20%-30%. Consequently, any transaction would either require a significant level of debt or dilution to Stryker shareholders, the analyst contends. He sees the potential deal as likely being dilutive until 2021. O'Brien has an Overweight rating on Boston Scientific with a $32.50 price target. The stock closed the trading day up 7% to $34.32 after the Wall Street Journal reported that Stryker approached the company regarding a takeover.
06/08/18
PIPR
06/08/18
NO CHANGE
Target $93
PIPR
Overweight
Some Abbott patients switching to DexCom, says Piper Jaffray
Piper Jaffray analyst JP McKim says his analysis of weekly script data suggests the drop-out rate for Abbott's (ABT) Libre is around 40%, or "much higher" than DexCom (DXCM). Further, some of those patients are indeed switching to DexCom's G6, which just launched last week, McKim tells investors in a research note. The analyst views G6 as an important growth driver for DexCom and suspects it will drive accelerating adoption in Type 1 diabetes for continuous glucose monitoring. The McKim has an Overweight rating on the shares with a $93 price target. JPMorgan this morning upgraded DexCom to Overweight.
06/08/18
JPMS
06/08/18
UPGRADE
Target $115
JPMS
Overweight
JPMorgan upgrades 'clear market leader' DexCom with $115 price target
JPMorgan analyst Robbie Marcus upgraded DexCom (DXCM) to Overweight from Neutral and raised his price target for the shares to $115 from $80. Glucose measurement is becoming an essential tool for patients and DexCom, with the launch of the G6, is the "clear market leader" from a technological standpoint, Marcus tells investors in a research note. Within two years the company is slated to have a low-cost, fully disposable option to counter Abbott's (ABT) Libre and address the Type 2 patient population, the analyst adds. He sees "significant upside" to both near-term estimates and Dexcom's product pipeline.
AKCA Akcea Therapeutics
$26.37

0.13 (0.50%)

05/11/18
WELS
05/11/18
UPGRADE
WELS
Outperform
Akcea Therapeutics upgraded to Outperform from Market Perform at Wells Fargo
05/11/18
STFL
05/11/18
NO CHANGE
Target $25
STFL
Hold
Akcea clarity improved by panel vote, but challenges remain, says Stifel
Stifel analyst Stephen Willey said the FDA Advisory Committee's vote in favor of supporting the approval of volanesorsen improves the regulatory clarity for Akcea Therapeutics, but he believes commentary from both voting members and FDA reviewers would suggest there's still "tangible risk" to the formal FDA decision due on August 30. He has reduced his peak worldwide sales estimates to approximately $200M in an effort to better reflect the high proportion of patient discontinuations and dose-reductions occurring within clinical development, which lowered his price target on Akcea shares to $25 from $30. Willey keeps a Hold rating on the stock.
05/11/18
WELS
05/11/18
UPGRADE
Target $33
WELS
Outperform
Akcea upgraded to Outperform with $33 target at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics to Outperform from Market Perform after an FDA panel voted 12-8 to support approval of Waylivra for the treatment of people with familial chylomicronemia syndrome. The analyst expects the vote to support approval of the drug by the August 30 action date. He raised his price target for Akcea shares to $33 from $30.
03/19/18
03/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arista Networks (ANET) downgraded to Sell from Hold at Deutsche Bank with analyst Vijay Bhagavath saying he is more cautious on the company's beat and raise story after his primary research indicated volatility in product orders. 2. GrubHub (GRUB) downgraded to Hold from Buy at Stifel with analyst John Egbert citing valuation as near-term risk/reward appears balanced at current levels. 3. Akcea Therapeutics (AKCA) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jim Birchenough saying he sees the shares as fairly valued ahead of the expected volanesorsen approval and launch by July 6. 4. Zoetis (ZTS) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying shares are approaching his $87 price and now sees more balanced risk/reward. 5. Suburban Propane (SPH) and AmeriGas (APU) were downgraded to Underweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$185.32

0.46 (0.25%)

06/25/18
JEFF
06/25/18
NO CHANGE
Target $200
JEFF
Buy
Amgen's Neulasta franchise 'more durable' than Street expects, says Jefferies
Jefferies analyst Michael Yee notes that Mylan's (MYL) Neulasta biosimilar Fulphila will launch in the coming weeks, which poses a risk for Amgen (AMGN), but he tells investors in a research note that "We already knew a biosimilar was coming anyway" and this news does not alter his thesis. Yee says the Street already models some Neulasta decline, which is reflected by Amgen's multi-year low P/E multiple, and contends that, based on precedence, he thinks the Neulasta franchise might be more durable than the Street expects.
06/22/18
MSCO
06/22/18
NO CHANGE
Target $200
MSCO
Overweight
Amgen may be pressured by IMS restatement for Aimovig, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that IMS announced that it has overstated the mail order volume for Amgen's Aimovig and will amend its mail order method with this week's data and restate prior weeks next Friday. Preliminary figures indicate the restatement will lower overall total prescriptions by about 27%, said Harrison. He would expect pressure on Amgen shares given the perception negative, though he still thinks initial Aimovig demand is robust, Harrison tells investors. He keeps an Overweight rating and $200 price target on Amgen shares.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
AZN AstraZeneca
$34.97

-0.085 (-0.24%)

05/30/18
JEFF
05/30/18
NO CHANGE
Target $48
JEFF
Hold
Tesaro risk/reward 'skewed toward downside,' says Jefferies
Jefferies analyst Eun Yang believes Tesaro's (TSRO) risk/reward is "skewed toward downside" into AstraZeneca's (AZN) Phase 3 ovarian cancer data for Lynparza . A discussion with a key opinion leader points to high bar for clinical/commercial success, Yang tells investors in a research note. She points out that Zejula in first-line ovarian cancer accounts for greater than 40% of her $48 price target for Tesaro. The analyst keeps a Hold rating on the shares.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05/31/18
SBSH
05/31/18
NO CHANGE
Target $100
SBSH
Buy
Amid investor questions, Citi reiterates $100 target on Tesaro
Citi analyst Robyn Karnauskas says she's been getting a lot of investor questions on Tesaro (TSRO) around the impact of Avastin approval on PARP use in first-line ovarian cancer, ahead of AstraZeneca's (AZN) Solo-1 data expected in the first half of 2018. After speaking to Tesaro's CEO, the analyst continues to be constructive on the quarter. The company believes that eventually Avastin will mostly be used in combinations, Karnauskas tells investors in a research note. She thinks Tesaro shares "will emerge" with crucial data expected in the latter half of the year. The analyst reiterates a Buy rating on the shares with a $100 price target.
06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
BAYRY Bayer
$0.00

(0.00%)

04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
CL Colgate-Palmolive
$65.11

0.48 (0.74%)

05/25/18
ARGS
05/25/18
UPGRADE
Target $72
ARGS
Buy
Colgate-Palmolive upgraded to Buy at Argus on valuation
As reported earlier, Argus analyst John Eade upgraded Colgate-Palmolive to Buy from Hold with a price target of $72. The analyst says the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. Eade further states that his $72 price target implies a multiple of 21-times forward earnings, which is still below the midpoint of the company's historical range.
05/24/18
BERN
05/24/18
NO CHANGE
Target $72
BERN
Market Perform
Colgate-Palmolive could be target for activists, says Bernstein
Bernstein analyst Ali Dibadj says his sum-of-the-parts analysis suggests Colgate-Palmolive's businesses, even beyond Oral Care, could be attractive to other owners, with areas for improvement more notably across Home Care and Pet Food. The analyst believes the company's stock could be a target for activists given its more realistic current valuation, with various levers at play to drive fundamental improvement and earnings growth. Dibadj reiterates a Market Perform rating and $72 price target on the shares.
05/25/18
ARGS
05/25/18
UPGRADE
ARGS
Buy
Colgate-Palmolive upgraded to Buy from Hold at Argus
05/25/18
05/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes PayPal is in the early stages of transforming from an online checkout company to a global payments platform. 2. Novartis (NVS) upgraded to Neutral from Underperform at Credit Suisse. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at Argus analyst John Eade saying the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. 4. Best Inc. (BSTI) upgraded to Buy from Neutral at Citi. 5. Loma Negra (LOMA) upgraded to Outperform from Market Perform at Itau BBA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
DXCM DexCom
$95.48

-4.04 (-4.06%)

06/12/18
PIPR
06/12/18
NO CHANGE
Target $116
PIPR
Overweight
DexCom price target raised to $116 from $93 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for DexCom to $116 citing two new data points and his consumer continuous glucose monitoring survey. The first data point, that Centers for Medicare & Medicaid Services will now allow Medicare patients to use their smart phone with CGM including the share function is a slight positive for DexCom, McKim tells investors in a research note. The second data point, which is the analyst was not able to confirm, is UnitedHealth (UNH) maybe moving to a bundled payment for CGM. And thirdly, McKim says his May consumer survey confirms a continued shift to CGM with more Type 2s is coming into the market. He believes DexCom remains the best way to play this trend and that the G6 launch will be a "meaningful driver of growth." The analyst keeps an Overweight rating on the shares
06/08/18
06/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Outperform from Market Perform at Bernstein with analyst Bob Brackett saying the company's "stalwart global portfolio" and Brent pricing helps insulate it from Permian congestion impacting other E&Ps. 2. DexCom (DXCM) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying glucose measurement is becoming an essential tool for patients and DexCom, with the launch of the G6, is the "clear market leader" from a technological standpoint. 3. Penn National (PENN) reinstated with an Overweight from Neutral at JPMorgan with analyst Joseph Gref saying he sees a favorable setup for the shares given an "attractive regional gaming landscape" and the company's margin improvement initiatives. 4. Marathon Oil (MRO) upgraded to Buy from Hold at Tudor Pickering. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at William Blair with analyst Amanda Murphy citing the recent UnitedHealthcare (UNH) contract change and positive secular trends for larger labs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/18
JEFF
06/22/18
NO CHANGE
Target $115
JEFF
Buy
DexCom the 'clear leader' in data for Medtech, says Jefferies
Data is being "increasingly harnessed" in Medtech to improve clinical outcomes and lower costs, and DexCom (DXCM) is the clear leader, Jefferies analyst Raj Denhoy tells investors in a research note. Using data generated from continuous glucose monitors "unquestionably" improves the care and lowers the cost to treat Type 1 and Type 2 diabetics, unlocking significant value, the analyst adds. He believes DexCom is "very well positioned to capture that benefit" with the "unmatched performance" of its sensors and the relationships with other players in the space. Denhoy raised his price target for DexCom to $115 and keeps a Buy rating on the shares.
06/22/18
OPCO
06/22/18
NO CHANGE
Target $24
OPCO
Outperform
Tandem Diabetes' approval timing for Basal-IQ 'in-line,' says Oppenheimer
Oppenheimer analyst Steve Lichtman backed an Outperform rating and $24 price target on Tandem Diabetes Care (TNDM) after the company announced yesterday FDA approval of the t:slim X2 insulin pump with Basal-IQ which it plans to launch in August. In a research note to investors, Lichtman said that approval timing is in-line, though compatibility with Dexcom's (DXCM) new G6 sensor in the initial approval is upside to expectations. Lichtman remains "bullish" on shares with his above-consensus sales growth estimate in 2019 of +32% y/y and believes international estimates are too conservative.
LLY Eli Lilly
$85.82

-0.08 (-0.09%)

06/13/18
JEFF
06/13/18
DOWNGRADE
Target $50
JEFF
Hold
Armo BioSciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Armo BioSciences (ARMO) to Hold and lowered his price target for the shares to $50 from $61. The analyst expects the takeover by Eli Lilly (LLY) to close in a few weeks and does not expect a competing bid to emerge.
06/15/18
PIPR
06/15/18
NO CHANGE
Target $85
PIPR
Overweight
Piper Jaffray sees better than expected U.S. launch for Olumiant
Piper Jaffray analyst Tyler Van Buren says he left a meeting with CEO of Eli Lilly (LLY) David Ricks with increased conviction in the U.S. launch of Olumiant. The analyst believes the launch will be better than investors currently anticipate and reiterates an Overweight rating on shares of Incyte (INCY) with an $85 price target. Van Buren expect payors to be "very receptive" to Olumiant pricing.
IRWD Ironwood
$18.66

-0.69 (-3.57%)

05/30/18
WELS
05/30/18
NO CHANGE
Target $22
WELS
Outperform
Ironwood price target raised to $22 from $18 at Wells Fargo
Wells Fargo analyst David Maris raised his price target on Ironwood to $22 and kept his Outperform rating, saying he is updating his model following the company's Q1 earnings as well as its announcement of separating its soluble guanylate cyclase business. While the analyst also lowers his FY18 EPS view to (67c) from (38c) to reflect the separation, he adds that future commercial/GI-focused IRWD earnings should no longer be depressed by R&D spending on the sGC assets.
05/09/18
05/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Crocs (CROX) downgraded to Hold from Buy at Stifel with analyst Jim Duffy saying he believes the stock has "adequately" re-rated to discount fiscal 2019 earnings power. 2. Monster Beverage (MNST) downgraded to Neutral from Overweight at JPMorgan with analyst Andrea Teixeira saying she sees a "difficult road ahead" for the company following its first quarter results. 3. Adient (ADNT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying that recent management commentary appears to have taken the potential for strategic action involving the underperforming metals business off the table. 4. Ironwood (IRWD) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Lebowitz saying he believes management's target of Linzess U.S. sales exceeding $1B by 2020 could be a challenge given the recent deceleration in volume growth. 5. Papa John's (PZZA) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying he is concerned Papa John's may not have a recovery in comps in the near-term and recommends investors wait for a significant pullback and or evidence same-store-sales being to recover in the coming quarters before becoming constructive on shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/18
MSCO
05/09/18
DOWNGRADE
MSCO
Underweight
Ironwood downgraded to Underweight from Equal Weight at Morgan Stanley
05/09/18
05/09/18
DOWNGRADE
Target $13

Underweight
Ironwood downgraded to Underweight on Linzess growth concerns at Morgan Stanley
As previously reported, Morgan Stanley analyst David Lebowitz downgraded Ironwood to Underweight from Equal Weight as he believes management's target of Linzess U.S. sales exceeding $1B by 2020 could be a challenge given the recent deceleration in volume growth. Also, while the company has multiple mid-to-late stage pipeline products, Lebowitz is not yet comfortable enough with them to incorporate them into his valuation, he tells investors. He lowered his price target on Ironwood shares to $13 from $15.
JNJ Johnson & Johnson
$122.70

-0.11 (-0.09%)

06/12/18
FBCO
06/12/18
NO CHANGE
Target $151
FBCO
Outperform
Credit Suisse would be surprised to see J&J bid for Boston Scientific
Credit Suisse analyst Vamil Divan would be surprised to see Johnson & Johnson (JNJ) bid for Boston Scientific (BSX), following a report that Stryker (SYK) had approached Boston about a possible acquisition. In general, the analyst believes Johnson & Johnson prefers smaller, targeted acquisitions to larger deals and prefers to obtain technology at an earlier stage before the market has assigned proper value to it. Divan reiterates an Outperform rating and $151 price target on Johnson & Johnson shares.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
06/05/18
CANT
06/05/18
NO CHANGE
Target $510
CANT
Overweight
Medtronic robot delay 'clear positive' for Intuitive Surgical, says Cantor
Medtronic (MDT) today at its analyst meeting said it expects commercial launch of its surgical robot in fiscal 2020, which is roughly a year delay compared to the company's prior expectations, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note partially titled "ISRG's Headstart Gets Bigger." The analyst views the revised timing of the commercial launch of Medtronic's robot as a "clear positive" for Intuitive Surgical (ISRG). With the commercial launches of the Medtronic and Johnson & Johnson (JNJ) robots at least 18 months away, Intuitive should continue to grow its global installed base, further advancing its global surgical robotics leadership position, Bijou writes. He reiterates his Overweight rating on the shares with a $510 price target. The stock in afternoon trading is up $8.46 to $486.39.
MDT Medtronic
$86.73

-0.07 (-0.08%)

06/06/18
NEED
06/06/18
NO CHANGE
Target $103
NEED
Buy
Medtronic's financial targets 'achievable,' says Needham
Needham analyst Mike Matson raised his price target for Medtronic to $103 from $97 and reiterated a Buy rating following the company's investor day in New York City, which he says increased his confidence in the company's product portfolio and that its new financial targets, including organic revenue growth for FY18-FY22 of 4%+, adjusted EPS growth of 8%+ and operating margin expansion of 40-50bps per year, are "realistic" and "achievable."
06/06/18
WBLR
06/06/18
INITIATION
WBLR
Market Perform
Medtronic assumed with a Market Perform at William Blair
William Blair analyst Margaret Kaczor assumed coverage of Medtronic with a Market Perform rating. The analyst believes it will be difficult for the company to grow sales above 4% without the help of acquisitions.
06/18/18
PIPR
06/18/18
NO CHANGE
Target $96
PIPR
Overweight
Piper continues to recommend Medtronic after management meeting
After meeting with management, Piper Jaffray analyst Matt O'Brien continues to recommend building positions in Medtronic (MDT). The analyst views management's 4% plus revenue outlook over the next several years as "readily achievable and likely conservative." Management noted that given the low penetration rates of surgery performed on robots, they did not see a reason to be aggressive on pricing of their system once they get it to market, O'Brien tells investors in a research note. He believes that is a positive comment for Intuitive Surgical (ISRG). The analyst keeps an Overweight rating on Medtronic with a $96 price target.
MNKD MannKind
$2.02

0.04 (2.02%)

03/01/18
MAXM
03/01/18
DOWNGRADE
Target $1
MAXM
Sell
MannKind downgraded to Sell at Maxim on disappointing Q4 Afrezza sales
As reported earlier, Maxim analyst Jason Kolbert downgraded MannKind to Sell from Hold with a $1 price target, saying the company's Afrezza revenues of $4.5M were at the lower end of recently-lowered guidance and were " clearly disappointing given management's robust marketing plans". Kolbert adds that the company has just $44M of cash remaining, having burned through about $120M last year.
05/10/18
HCWC
05/10/18
NO CHANGE
Target $5
HCWC
Buy
MannKind price target lowered to $5 from $7 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $5 citing a slower Afrezza ramp following the company's Q1 results. The analyst, however, still projects Afrezza having over $500M of sales potential. He keeps a Buy rating on the shares.
03/01/18
03/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Campbell Soup (CPB) downgraded to Underweight from Neutral at Piper Jaffray by analyst Michael Lavery, who sees multiple expansion as unlikely given his expectations for 1%-1.5% earnings growth in fiscal 2019. Higher interest rates and lower than expected Snyder-Lance operating contribution weigh on the analyst's earnings expectations. 2. MannKind (MNKD) downgraded to Sell from Hold at Maxim by analyst Jason Kolbert, who said the company's Afrezza revenues of $4.5M were at the lower end of recently-lowered guidance and were " clearly disappointing given management's robust marketing plans". Kolbert added that the company has just $44M of cash remaining, having burned through about $120M last year. 3. Darling Ingredients (DAR) downgraded to Neutral from Buy at Goldman Sachs by analyst Adam Samuelson. While the company's Q4 results came in modestly above expectations, the analyst finds the outlook for roughly flat EBITDA in the base business despite recent growth investments disappointing. Samuelson sees a less attractive risk/reward for Darling post the Q4 results. Shares were also downgraded to Market Perform from Outperform at BMO Capital by analyst Kenneth Zaslow, who said his undamental view on the company has not changed, pointing to less compelling risk-reward based on limited upside in the stock price and some near-term headwinds. 4. Gibraltar Industries (ROCK) downgraded to Sector Weight from Overweight at KeyBanc by analyst Kenneth Zener, who said the risk to return is currently balanced. The analyst awais clarity on the company's next portfolio addition and wants to sees a "steady cadence of Solar EBIT margins." He believes, however, the Gibraltar is executing well post its Q4 results. 5. Mohawk (MHK) downgraded to Buy from Conviction Buy at Goldman Sachs. Analyst Samuel Eisner removed Mohawk from the Conviction Buy List citing near-term risks from rising rates and 1H18 risks from increasing costs and ramping capacity that could put a lid on shares near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/18
HCWC
06/07/18
NO CHANGE
Target $5
HCWC
Buy
MannKind's treprostinil could be 'transformational asset,' says H.C. Wainwright
MannKind's (MNKD) announcement this morning of a successful Phase 1 completion of its Technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension comes months ahead of schedule, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The news is an important reminder that MannKind's inhalation drug delivery platforms offer potentially much more value than just Afrezza inhalable insulin, the analyst contends. He believes inhalable treprostinil, which is not yet in his model, could "ultimately prove a transformational asset." Livnat points out that United Therapeutics' (UTHR) pulmonary arterial hypertension treprostinil franchise is estimated to deliver over $1.1B of sales in 2018. The analyst keeps a Buy rating on MannKind with a $5 price target.
WAKE Wake Forest Bancshares Inc.
$0.00

(0.00%)

VLRX Valeritas
$1.61

0.22 (15.83%)

07/10/17
WEDB
07/10/17
INITIATION
Target $12
WEDB
Outperform
Valeritas initiated with an Outperform at Wedbush
Pre-open, Wedbush analyst Tao Levy initiated Valeritas with an Outperform and a $12 price target telling investors the company is well positioned to increase adoption of its V-Go platform, a wearable insulin delivery device, after recently raising additional capital and completing a significant adjustment in its commercialization strategy.
03/28/18
03/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sell from Hold at DZ Bank. 2. Valeritas (VLRX) downgraded to Market Perform from Outperform at Cowen. 3. Tallgrass Energy Partners (TEP) downgraded to Hold from Buy at Stifel with analyst Selman Akyol saying the agreement for Tallgrass Energy GP (TEGP) to buy Tallgrass Energy Partners in a unit-for-share exchange was mostly as expected. 4. Northern Star (NESRF) downgraded to Market Perform from Outperform at BMO Capital. 5. Japan Airlines (JAPSY) downgraded to Hold from Buy at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/18
COWN
03/28/18
DOWNGRADE
COWN
Market Perform
Valeritas downgraded to Market Perform from Outperform at Cowen
Cowen analyst Doug Schenkel downgraded Valeritas to Market Perform.
TNDM TNDM

06/22/18
PIPR
06/22/18
NO CHANGE
Target $25
PIPR
Overweight
Tandem Diabetes price target raised to $25 from $13 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for Tandem Diabetes to $25 following FDA approval of the company's t:slim X2 Insulin Pump with Basal-IQ. Having a system like Basal-IQ to be paired with no finger stick G6 is a "game changer," McKim tells investors in a research note. The 670G is patient intensive requiring four-to-eight finger sticks a day, and while Basal-IQ is not a hybrid closed loop, it eliminates finger sticks for patients, the analyst points out. He expects the approval to attract competitive wins for Tandem, especially Animas patients, and give the company's install base an attractive reason to upgrade to a new pump. The analyst keeps an Overweight rating on Tandem Diabetes.
06/18/18
LSCM
06/18/18
INITIATION
Target $30
LSCM
Buy
Tandem Diabetes initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil started Tandem Diabetes with a Buy rating and $30 price target. The company is "poised for rapid growth in the insulin pump market," O'Neil tells investors in a research note. He expects FDA approval of Tandem's newest insulin pump, integrated with Dexcom's G5 continuous glucose monitor.
06/18/18
OPCO
06/18/18
NO CHANGE
Target $24
OPCO
Outperform
Tandem Diabetes price target raised to $24 from $15 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $24 from $15 given catalysts ahead and as the stock continues trades at a discount to high-growth medtech peers. The analyst reiterates an Outperform rating on the shares.
SNY Sanofi
$40.48

0.5 (1.25%)

04/27/18
PIPR
04/27/18
NO CHANGE
PIPR
Regeneron's Q1 'won't be pretty' based on Sanofi results, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond notes that Sanofi (SNY) this morning reported Q1 results, including revenue numbers for Dupixent, Praluent and Kevzara. All three missed consensus, but importantly, demand trends appear intact for Dupixent, with its miss driven by inventory fluctuations and seasonality, Raymond tells investors in a research note on Regeneron Pharmaceuticals (REGN) titled "Sanofi Read-Through: Looks Like Q118 Won't Be Very Pretty." He has an Overweight rating on Regeneron with a $500 price target.
04/27/18
MSCO
04/27/18
NO CHANGE
Target $400
MSCO
Equal Weight
Regeneron slide after Sanofi report an overreaction, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Sanofi's (SNY) report of Q1 earnings included details on worldwide sales for Regeneron (REGN) partnered products Dupixent, Praluent and Kevzara and that all three products missed consensus estimates. He believes investors are primarily concerned by the large Dupixent miss, as its sales were about 22% below the consensus forecast. However, Sanofi indicated that patient volumes continue to trend favorably and that Dupixent was hurt by greater patient assistance and inventory drawdown in the quarter. While he understands the reaction, he also views it as overdone, Harrison said, maintaining a $400 price target and Equal Weight rating on Regeneron shares.
05/23/18
LEHM
05/23/18
NO CHANGE
Target $290
LEHM
Underweight
Regeneron product concentration remains big risk, says Barclays
Barclays analyst Geoff Meacham says his analysis suggests Eylea concentration remains a big risk for Regeneron Pharmaceuticals (REGN). A scenario analysis shows the company's adjusted earnings is sensitive to even modest changes to U.S. Eylea sales versus any product under the Sanofi (SNY) joint venture, namely Dupixent, Praluent, and Kevzara, Meacham tells investors in a research note. The analyst reiterates an Underweight rating on Regeneron with a $290 price target.
SIEGY Siemens
$0.00

(0.00%)

04/17/18
UBSW
04/17/18
NO CHANGE
UBSW
Buy
Siemens undervalued ahead of catalysts, says UBS
UBS analyst Markus Mittermaier believes Siemens shares have a price disconnect from the company's fundamentals. He noted there are issues weighing down the shares, such as India market issues and the gas turbine market forecast, but he believes these issues are understood. The analyst sees a number of catalysts ahead and believes investors should focus on the positive story. Mittermaier reiterated his Buy rating on Siemens shares.
04/02/18
VERT
04/02/18
UPGRADE
VERT
Buy
Siemens upgraded to Buy from Hold at Vertical Research
12/05/17
LEHM
12/05/17
DOWNGRADE
LEHM
Underweight
Siemens downgraded to Underweight from Equal Weight at Barclays
Barclays analyst James Stettler downgraded Siemens to Underweight and lowered his price target for the shares to EUR 110 from EUR 125.
12/11/17
MSCO
12/11/17
UPGRADE
MSCO
Overweight
Siemens upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Ben Uglow upgraded Siemens to Overweight with a price target of EUR 134.
SENS Senseonics
$4.30

-0.46 (-9.66%)

04/04/18
04/04/18
INITIATION

Neutral
Guggenheim starts Dexcom at Neutral, Insulet and Senseonics at Buy
As previously reported, Guggenheim analyst Chris Pasquale initiated Dexcom (DXCM) with a Neutral rating. While he is bullish on the outlook for CGM adoption and Dexcom's ability to sustain a leadership position in the market, his recent survey work suggests the company could be at risk from both a share and pricing perspective as the field enters a disruptive phase with a rapid influx of new technologies. Pasquale also initiated diabetes market player Insulet (PODD) with a Buy rating and $105 price target, calling it "a good story poised to get even better as its pipeline matures." His surveys suggests Insulet is well positioned to take insulin pump share going forward, Pasquale tells investors. Also in the diabetes space, Pasquale started Senseonics (SENS) with a Buy rating and $6 price target, identifying its Eversense long-term implantable system as a differentiated new entrant into the continuous glucose monitoring market that he expects will appeal to diabetic patients.
06/11/18
CHLM
06/11/18
INITIATION
Target $6.5
CHLM
Buy
Senseonics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started Senseonics with a Buy rating and $6.50 price target while noting that its novel continuous glucose monitor is nearing FDA approval and a largely untapped $23B market opportunity awaits.
06/22/18
ADAM
06/22/18
NO CHANGE
Target $6
ADAM
Buy
Senseonics FDA approval in time for major push at ADA, says Canaccord
Canaccord analyst Kyle Rose said the FDA approval of Senseonics' 90-day Eversense CGM system comes just in time for a major push at this year's ADA conference, which begins tomorrow. He noted the initial commercial team is in place for a U.S. launch and he hopes to get a pulse on the market's excitement at the conference for the upcoming launch. Rose reiterated his Buy rating and raised his price target to $6 from $5 on Senseonics shares.
06/22/18
CHLM
06/22/18
NO CHANGE
Target $6.5
CHLM
Buy
Senseonics 'cleared a major hurdle' with FDA approval, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak reiterated a Buy rating and $6.50 price target on Senseonics after the company's premarket application for Eversense CGM system was approved by the FDA. In a research note to investors, Nowak said that while it was clear the market was expecting approval, the company "cleared a major hurdle" and sees shares continuing to rise as the company pivots from an early-stage company with approval risk to a commercial-stage company with execution risk. Nowak also noted that on an investor call on the FDA approval, the company confirmed that the Eversense U.S. label is consistent with the PMA application.
REGN Regeneron
$327.60

-4.22 (-1.27%)

05/04/18
LEER
05/04/18
NO CHANGE
Target $435
LEER
Outperform
Regeneron price target lowered to $435 from $502 at Leerink
Leerink analyst Geoffrey Porges noted that Regeneron reported mixed Q1 results, stating that Eylea "reassuringly" beat consensus but Dupixent, Kevzara and Praluent fell short of consensus estimates. The big question for Q2 will be the magnitude of recovery in U.S. Dupixent sales, said Porges, who believes better performance for Dupixent, sustained growth in Eylea, growth in Praluent and initial sales of cemiplimab are all essential for Regeneron's stock to recover in the second half of 2018. He maintains an Outperform rating on the stock but lowered his Regeneron price target to $435 from $502.
05/07/18
RBCM
05/07/18
NO CHANGE
Target $342
RBCM
Sector Perform
Regeneron price target lowered to $342 from $430 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Regeneron to $342 and kept his Sector Perform rating. The analyst says that while Eylea sales exceeded his expectations in Q1, he sees continued pressure for the stock from increasing competition for both Eylea and Dupixent as well as a reimbursement pushback for the latter, reducing his sales expectations on both of these programs.
05/08/18
PIPR
05/08/18
NO CHANGE
Target $450
PIPR
Overweight
Piper survey shows 'significant progress' for Regeneron's Dupixent
Piper Jaffray analyst Christopher Raymond says his new survey work indicates "significant progress" for Regeneron Pharmaceuticals' Dupixent both in terms of the drug's quantitative use trends and dermatologists' qualitative views of the drug's commercialization. As such, the analyst believes Dupixent is poised for a "sharp rebound" beginning this quarter, with "significant follow-through" for the remainder of 2018. He maintains above consensus estimates on Dupixent and would be buyers of Regeneron shares on the weakness. Despite the "dismal" year-to-date performance, the stock can "rebound nicely especially on any sign of unexpected commercial traction," Raymond tells investors in a research note. He keeps an Overweight rating on Regeneron with a $450 price target.
PODD Insulet
$91.35

-6.02 (-6.18%)

05/03/18
PIPR
05/03/18
NO CHANGE
Target $90
PIPR
Overweight
Insulet price target raised to $90 at Piper Jaffray on management confidence
Piper Jaffray analyst JP Kim raised his price target on Insulet to $90 from $88 and kept his Overweight rating, citing the company's Q1 earnings beat and a conference call showcasing the management "oozing with confidence". Kim further notes that Insulet stands to benefit from the tailwinds in Animas, UNH and Medicare, along with a "flawless" execution by the management. The analyst adds that the tone of the call was even more bullish than the updated increase in guidance would suggest, which could result in another FY18 view upgrade after the release of Q2 results.
04/20/18
BREN
04/20/18
INITIATION
Target $100
BREN
Buy
Insulet initiated with a Buy at Berenberg
Berenberg initiated Insulet with a Buy and $100 price target.
06/04/18
PIPR
06/04/18
NO CHANGE
Target $106
PIPR
Overweight
Insulet price target raised to $106 from $90 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for Insulet to $106 after the company announced the approval of Dash. While Dash coming free with the purchase of pods is slight revenue and gross margin headwind, it will greatly improve patient access, more than offsetting these headwinds, McKim tells investors in a research note. He continues to recommend investors own the stock and keeps an Overweight rating on Insulet.
04/17/18
PIPR
04/17/18
NO CHANGE
PIPR
J&J commentary positive for pure-play spine names, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is out discussing derivative calls following Johnson & Johnson's (JNJ) Q1 results. The orthopedic market looked relatively stable, though Hips were notably softer than expected, O'Brien tells investors in a research note. He believes Stryker (SYK) is "clearly taking market share," which he views as an incremental negative for Zimmer Biomet (ZBH). On Spine, some U.S. weakness was expected, but J&J's results could be viewed as concerning given continued weakness since Q3 of 2017, the analyst adds. He thinks the end markets "are ok" and the commentary on J&J losing share benefits pure-play spine names NuVasive (NUVA), Globus Medical (GMED), SeaSpine (SPNE) and K2M Group (KTWO). He believes the pure-plays continue to out-innovate and take share despite the weakness in the overall category. Johnson & Johnson's results also show that the U.S. lens market remains strong and is shifting to 1-Days lenses from weeklies/monthlies, which is a positive for Cooper Companies (COO), O'Brien contends. Lastly, the analyst says the decline in J&J's U.S. diabetes franchise from the Animas exit was faster than expected. This is good for the pump names Insulet (PODD) and Tandem Diabetes (TNDM) and a slight negative for Dexcom (DXCM) as some of those will end up at Medtronic (MDT), O'Brien argues. He continues to believe that both Insulet and Tandem "will gain more than their fair share" of Animas patients.
NVO Novo Nordisk
$46.98

0.14 (0.30%)

02/26/18
JPMS
02/26/18
NO CHANGE
Target $105
JPMS
Overweight
Concerns over Eli Lilly diabetes franchise overdone, says JPMorgan
JPMorgan analyst Chris Schott believes longer-term growth concerns surrounding Trulicity and Eli Lilly's (LLY) broader diabetes franchise are overdone following Novo Nordisk's (NVO) oral semaglutide results as well as the launch of Ozempic. The analyst sees a buying opportunity in shares of Eli Lilly following the recent pullback. Lilly is a "highly diversified growth story" and competition to Trulicity is manageable, Schott tells investors in a research note. He keeps an Overweight rating on the shares with a $105 price target.
01/22/18
FBCO
01/22/18
DOWNGRADE
Target $82
FBCO
Underperform
Credit Suisse downgrades Lilly to Underperform on mid-term guidance concerns
Credit Suisse analyst Vamil Divan downgraded Eli Lilly (LLY) to Underperform from Neutral and cut his price target for the shares to $82 from $88. The analyst does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. Divan notes he's $500M below consensus for Trulicity in 2021 based on market share gains for Novo Nordisk's (NVO) Victoza following its recent label expansion, the threat from Novo's once-weekly Ozempic and risk from upcoming Phase 3 data for Novo's oral semaglutide. Trulicity accounts for 40% of Lilly's sales growth from 2016-2021 based on current expectations, Divan tells investors in a research note partially titled "Diabetes Challenges Leave Sour Taste in Our Mouth"
04/05/18
RHCO
04/05/18
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly supported by positive oncology and diabetes findings, says SunTrust
SunTrust analyst John Boris keeps his Buy rating and $101 price target on Eli Lilly (LLY), citing the latest developments in Oncology and Diabetes. In Oncology, Boris points to the positive Overall Survival and Progression Free Survival data for Cyramza in second-line hepatocellular carcinoma, though he sees the commercial opportunity in Hepatocellular Carcinoma as limited. In Diabetes, the analyst points to the latest data showing Trulicity gaining market share on Novo Nordisk's (NVO) Victoza in the GLP-1 market.
MRK Merck
$61.07

-0.39 (-0.63%)

05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.

TODAY'S FREE FLY STORIES

EGAN

eGain

$13.18

-0.725 (-5.22%)

16:13
07/18/18
07/18
16:13
07/18/18
16:13
Initiation
eGain initiated  »

eGain initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$129.46

-5.54 (-4.10%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Initiation
Clorox initiated  »

Clorox initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

AA

Alcoa

$47.85

-0.155 (-0.32%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Hot Stocks
Alcoa cuts FY18 adjusted EBITDA view to $3B-$3.2B from $3.5B-$3.7B »

The new full-year…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TBK

Triumph Bancorp

$41.15

0.45 (1.11%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Earnings
Triumph Bancorp reports Q2 adj. EPS 50c, consensus 50c »

Adjusted diluted earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 31

    Jul

  • 24

    Sep

AXP

American Express

$102.98

1.84 (1.82%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Hot Stocks
American Express says resuming buybacks this quarter »

Q2 consolidated total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

ON

ON Semiconductor

$24.24

0.34 (1.42%)

16:12
07/18/18
07/18
16:12
07/18/18
16:12
Initiation
ON Semiconductor initiated  »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 07

    Aug

  • 08

    May

BMCH

BMC Stock Holdings

$21.70

0.1 (0.46%)

16:11
07/18/18
07/18
16:11
07/18/18
16:11
Initiation
BMC Stock Holdings initiated  »

BMC Stock Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AA

Alcoa

$47.94

-0.065 (-0.14%)

16:10
07/18/18
07/18
16:10
07/18/18
16:10
Earnings
Alcoa reports Q2 EPS ex-items $1.52, consensus $1.34 »

Reports Q2 revenue $3.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AXP

American Express

$102.96

1.82 (1.80%)

16:10
07/18/18
07/18
16:10
07/18/18
16:10
Hot Stocks
American Express reaffirms FY18 EPS view at high-end of $6.90-$7.30 view »

FY18 EPS consensus $7.24.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

KMI

Kinder Morgan

$17.77

0.075 (0.42%)

16:09
07/18/18
07/18
16:09
07/18/18
16:09
Earnings
Kinder Morgan backs FY18 adjusted EBITDA view of roughly $7.5B »

For 2018, KMI's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FBNK

First Connecticut

$30.95

(0.00%)

16:09
07/18/18
07/18
16:09
07/18/18
16:09
Earnings
First Connecticut reports Q2 EPS 42c, consensus 40c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$102.93

1.79 (1.77%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
American Express reports Q2 EPS $1.84, consensus $1.82 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

KMI

Kinder Morgan

$17.80

0.11 (0.62%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
Kinder Morgan reports Q2 adjusted EPS 21c, consensus 19c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GBNK

Guaranty Bancorp

$30.70

0.25 (0.82%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Earnings
Breaking Earnings news story on Guaranty Bancorp »

Guaranty Bancorp reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$98.27

-0.64 (-0.65%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Hot Stocks
PTC advances transition to subscription business model »

PTC announced a milestone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GBX

Greenbrier

$55.10

0.25 (0.46%)

16:08
07/18/18
07/18
16:08
07/18/18
16:08
Initiation
Greenbrier initiated  »

Greenbrier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFPI

Universal Forest

$38.35

-0.205 (-0.53%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
Universal Forest reports Q2 EPS 71c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLG

SL Green Realty

$100.51

0.29 (0.29%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Earnings
SL Green Realty reports Q2 FFO $1.69, consensus $1.68 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ICFI

ICF International

$72.50

-0.5 (-0.68%)

16:07
07/18/18
07/18
16:07
07/18/18
16:07
Hot Stocks
ICF International awarded infrastructure contract by LA County Public Works »

ICF has been selected by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TCBI

Texas Capital

$94.00

2.2 (2.40%)

16:06
07/18/18
07/18
16:06
07/18/18
16:06
Earnings
Texas Capital reports Q2 EPS $1.38, consensus $1.39 »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

IBM

IBM

$144.32

0.86 (0.60%)

16:06
07/18/18
07/18
16:06
07/18/18
16:06
Earnings
IBM reports Q2 cognitive solutions revenue $4.6B, flat y/y »

Reports Q2 global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

IBM

IBM

$144.32

0.86 (0.60%)

16:05
07/18/18
07/18
16:05
07/18/18
16:05
Hot Stocks
IBM says strategic imperatives revenue was $39B over last 12 months »

Strategic imperatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

PTC

PTC

$98.13

-0.78 (-0.79%)

16:05
07/18/18
07/18
16:05
07/18/18
16:05
Earnings
PTC sees FY18 EPS $1.41-$1.46, consensus $1.39 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DWCH

Datawatch

$11.30

-0.3 (-2.59%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
Datawatch reports Q3 EPS 7c, consensus (5c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 16

    Aug

PFBC

Preferred Bank

$63.93

0.18 (0.28%)

16:04
07/18/18
07/18
16:04
07/18/18
16:04
Earnings
Preferred Bank reports Q2 EPS $1.14, consensus $1.09 »

Q2 net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Sep

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.